Article

Abnormalities in the NF-kappaB family and related proteins in endometrial carcinoma. J Pathol

Universitat de Lleida, Lérida, Catalonia, Spain
The Journal of Pathology (Impact Factor: 7.43). 12/2004; 204(5):569 - 577. DOI: 10.1002/path.1666

ABSTRACT

The NF-κB family of transcription factors regulates a wide variety of cellular processes including cell growth, differentiation, and apoptosis. A tissue microarray was constructed from paraffin wax-embedded blocks from 95 endometrial carcinomas (EC), previously studied for microsatellite instability, as well as for alterations in PTEN, k-RAS and beta-catenin. Immunohistochemical evaluation included members of the NF-κB (p50, p65, p52, c-Rel, Rel-B) and the IκB (IκBα, IκBβ, IκBε, Bcl-3) families, as well as putative targets of NF-κB such as Flip, Bcl-xL, Cyclin D1, and oestrogen and progesterone receptors. Results were correlated with the clinical and pathological data. Nuclear immunostaining for members of the NF-κB family was frequent in EC (p50, 20%; p65, 16.5–21.9%; p52, 9.3%; c-Rel, 48.9%; Rel-B, 15.7%); and it correlated with negativity for members of the IκB family in some cases. There was a statistically significant association between immunoreaction for p50 and p65 (p = 0.006), suggesting activation of the so-called ‘classic form’ of NF-κB, similar to that described in breast cancer. Bcl-3 nuclear immunostaining was detected in 60.7% of cases. The vast majority of p52-positive tumours showed Bcl-3 nuclear immunoreaction (p = 0.038). Immunostaining for putative targets of NF-κB was as follows: Bcl-xL, 76.2% (p = 0.001); Flip 43.0%; Cyclin D1, 64.79%. p65 immunostaining correlated with increased immunoreaction for steroid hormone receptors. No correlation was found between NF-κB nuclear pattern and the presence of microsatellite instability, or alterations in PTEN, k-RAS, or beta-catenin. These results suggest that the NF-κB and IκB families of genes may be important in endometrial carcinogenesis, by controlling apoptosis and cell proliferation. Copyright © 2004 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Download full-text

Full-text

Available from: David Llobet-Navas, May 31, 2014
  • Source
    • "In contrast, Type 2 tumors are associated with p53 and ERBB-2 (HER-2/neu) mutations and loss of heterozygosity on several chromosomes , and in most cases are not diploid [7] [8] [9]. Systemic hormonal and chemotherapeutic treatments represent the cornerstones of advanced and recurrent endometrial cancer management , although it is still characterized by a poor prognosis. "
    [Show abstract] [Hide abstract]
    ABSTRACT: This study evaluated the potential ability of MK-0646 to inhibit IGF1-mediated biological actions and cell signaling events in Type 1 and Type 2 endometrial cancer. We found that MK-0646 treatment significantly decreased IGF1R expression. In addition, pretreatment with MK-0646 decreased the IGF1-induced phosphorylation of IGF1R, AKT and ERK. Apoptosis analyses showed that MK-0646 abolished the anti-apoptotic effect of IGF1. Furthermore, MK-0646 treatment abolished the IGF1-stimulatory effect on proliferation and enhanced the cytotoxic effect of cisplatin. These findings indicate that specific inhibition of IGF1R could be a useful therapeutic approach for Type 1 and Type 2 endometrial cancer.
    Full-text · Article · Feb 2013 · Cancer letters
  • Source
    • "This will lead to the identification of novel therapeutic targets that could improve patient's prognosis and treatment outcomes. It is well known that the NFkB pathway is constitutively activated in many cancers (Karin et al., 2002; Sosman and Puzanov, 2006), including endometrial carcinoma (Pallares et al., 2004). This pathway controls several critical processes such as cell growth, differentiation and apoptosis (Karin et al., 2002) and its dysregulation can induce cell transformation . "
    [Show abstract] [Hide abstract]
    ABSTRACT: Endometrial carcinoma is one of the most common malignancies in the female genital tract, usually treated by surgery and radiotherapy. Chemotherapy is used when endometrial carcinoma is associated with widespread metastasis or when the tumor recurs after radiation therapy. In the present study, we demonstrate that the tyrosine kinase receptor inhibitor Sunitinib reduces cell viability, proliferation, clonogenicity and induces apoptotic cell death in endometrial carcinoma cell lines, which is not due to its action through the most known targets like VEGFR, nor through EGFR as demonstrated in this work. Interestingly, Sunitinib reduces NFκB transcriptional activity either at basal level or activation by EGF or TNF-α. We observed that Sunitinib was able to inhibit the Bortezomib-induced NFκB transcriptional activity which correlates with a decrease of the phosphorylated levels of IKKα and β, p65 and IκBα. We evaluated the nature of the interaction between Sunitinib and Bortezomib by the dose effect method and identified a synergistic effect (combination index < 1). Analogously, silencing of p65 expression by lentiviral-mediated short-hairpin RNA delivery in Bortezomib treated cells leads to a strongly increased sensitivity to Bortezomib apoptotic cell death. Altogether our results suggest that the combination of Sunitinib and Bortezomib could be considered a promising treatment for endometrial carcinoma after failure of surgery and radiation.
    Preview · Article · Jul 2012 · Molecular oncology
  • Source
    • "This effect is mediated by its association with the NF-kappa B homodimers, p50 and p52, along with coactivators such as CBP/p300, SRC-1 and Tip60 [4,6]. While Bcl-3 overexpression was originally found to be associated with CLL and lymphomas, recent reports have shown that this oncogene is overexpressed in several solid tumors, such as breast [7], nasopharyngeal [8] and endometrial [9] carcinomas. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Bcl-3 is an atypical member of the inhibitor of NF-kappa B family of proteins since it can function as a coactivator of transcription. Although this oncogene was described in leukemia, it is overexpressed in a number of solid tumors as well. The oncogenic potential of Bcl-3 has been associated with its capacity to increase proliferation by means of activating the cyclin D1 promoter and to its antiapoptotic role mediated by the inhibiton of p53 activity. In the course of dissecting these properties, we found that depleting Bcl-3 protein using shRNAs induce a decrease of proliferation and clonogenic survival associated with the induction of multinucleation and increased ploidy. These effects were associated with a DNA damage response, a delay in G2/M checkpoint and the induction of centrosome amplification.
    Full-text · Article · Aug 2010 · Molecular Cancer
Show more